Although the targeted cancer treatment drug crizotinib is very effective in causing rapid regression of a particular form of lung cancer, patients' tumors inevitably become resistant to the drug. Now a new drug called ceritinib ...
Mar 26, 2014
0
0
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for ...
Sep 25, 2018
0
5
Treatment with the targeted therapy drug crizotinib effectively halts the growth of lung tumors driven by rearrangements of the ROS1 gene. In an article receiving Online First publication in the New England Journal of Medicine ...
Sep 27, 2014
0
1
Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials are created equal, and ...
May 30, 2019
0
2
A blood test to regularly monitor for the presence of rearrangement of the EML4-ALK gene fusion in patients with non-small cell lung cancer (NSCLC) may help clinicians predict the outcome of treatment with crizotinib, according ...
Apr 20, 2015
0
11
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients ...
Aug 8, 2020
0
2
A University of Kentucky Markey Cancer Center research team identified an existing cancer drug that shows promise as a treatment for the most common type of non-small cell lung cancer.
Jul 19, 2023
0
1
Patient-reported outcomes from the phase III CROWN study showed that time to treatment deterioration (TTD) in pain in chest, dyspnea, and cough was comparable between those who received lorlatinib and patients who took crizotinib. ...
Jan 31, 2021
0
3
Updated results of the global phase III ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell lung cancer show a median progression-free survival (PFS) of 34.8 months in ...
Jun 3, 2018
0
8
PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results ...
Oct 20, 2013
0
0
